Comparative oncology clinical trials
Ended Awarded Last action
- Contract number
- 75N91020F00016
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $926,047
Award facts
- Contract value 52% obligated
-
- $926,047.00 Current, with exercised options
- $1,780,568.00 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | -$406,398 | |
| Terminate for Convenience | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,332,445 |
About this award
This is a delivery order contract awarded by the National Cancer Institute (NCI), a civilian agency, to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is for "Comparative Oncology Clinical Trials" and is related to the President's Department of Government Efficiency Cost Efficiency Initiative. The contract has a ceiling value of $1,780,568.00 and a completion date of September 24, 2025. It is a cost-plus-fixed-fee contract type and was not set aside for any specific business category. Leidos Biomedical Research Inc. is a Federally Funded Research and Development Center (FFRDC) contractor for the NCI, providing comprehensive biomedical research and facilities support services to federal agencies, with a focus on the National Institutes of Health (NIH).
Quick answers
Who was awarded contract 75N91020F00016?
75N91020F00016 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 25, 2020.
How much is contract 75N91020F00016 worth?
The government has obligated $926,047 on 75N91020F00016. Its potential value, with all options, is $1,780,568.
Is contract 75N91020F00016 an order under another contract?
Yes. 75N91020F00016 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91020F00016 competed?
The extent of competition for 75N91020F00016 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award